Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 67.84 1.21% 0.81
EGRX closed up 1.21 percent on Tuesday, September 18, 2018, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Up
See historical EGRX trend table...

Date Alert Name Type % Chg
Sep 18 Wide Bands Range Expansion 0.00%
Sep 18 Oversold Stochastic Weakness 0.00%
Sep 17 Wide Bands Range Expansion 1.21%
Sep 17 Oversold Stochastic Weakness 1.21%
Sep 14 NR7 Range Contraction 1.77%
Sep 14 NR7-2 Range Contraction 1.77%
Sep 14 Wide Bands Range Expansion 1.77%
Sep 14 Down 3 Days in a Row Weakness 1.77%
Sep 14 Oversold Stochastic Weakness 1.77%
Sep 13 NR7 Range Contraction 1.68%

Older signals for EGRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Is EGRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 85.66
52 Week Low 48.84
Average Volume 214,396
200-Day Moving Average 64.6782
50-Day Moving Average 76.858
20-Day Moving Average 72.1905
10-Day Moving Average 67.251
Average True Range 2.7656
ADX 36.57
+DI 10.6035
-DI 26.2703
Chandelier Exit (Long, 3 ATRs ) 74.0332
Chandelier Exit (Short, 3 ATRs ) 73.6268
Upper Bollinger Band 85.1693
Lower Bollinger Band 59.2117
Percent B (%b) 0.33
BandWidth 35.957086
MACD Line -3.0985
MACD Signal Line -2.8384
MACD Histogram -0.2601
Fundamentals Value
Market Cap 1.03 Billion
Num Shares 15.2 Million
EPS 5.96
Price-to-Earnings (P/E) Ratio 11.38
Price-to-Sales 3.34
Price-to-Book 4.96
PEG Ratio 0.95
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 70.65
Resistance 3 (R3) 70.55 69.51 70.18
Resistance 2 (R2) 69.51 68.80 69.56 70.02
Resistance 1 (R1) 68.68 68.36 69.10 68.78 69.87
Pivot Point 67.64 67.64 67.85 67.69 67.64
Support 1 (S1) 66.81 66.93 67.23 66.91 65.81
Support 2 (S2) 65.77 66.49 65.82 65.66
Support 3 (S3) 64.94 65.77 65.50
Support 4 (S4) 65.04